

Product Name: Fenretinide Revision Date: 01/10/2021

Product Data Sheet

Fenretinide

Cat. No.: A3412

CAS No.: 65646-68-6 **Formula:** C26H33NO2

M.Wt: 391.55

Synonyms: 4-HPR; (4-Hydroxyphenyl)retinamide

Target: Others

Pathway: RAR/RXR

Storage: Store at -20°C



insoluble in H2O; ≥19.6 mg/mL in DMSO; ≥47.8 mg/mL in EtOH with gentle warming

Mass Solvent 1mg 5mg 10mg Preparing Concentration Stock Solutions 1 mM 2.5540 mL 12.7698 mL 25.5395 mL 2.5540 mL 5 mM 0.5108 mL 5.1079 mL 10 mM 0.2554 mL1 1.2770 mL 2.5540 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

In Vitro

Shortsummary	Synthetic retinoid agonist	
IC ₅₀ & Target		
	Cell Viability Assay	
	Cell Line:	T-ALL cell lines, CCRF-CEM leukemia cells, CCRF-CEM and Jurkat cell,
		OVCAR-5 cell
In Vitro	Preparation method:	The solubility of this compound in DMSO is > 19.6 mg/mL. General tips for
		obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes
		and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
		below -20°C for several months.

	Reacting conditions:	>1 μM, 3 days	
	Applications:	Fenretinide inhibited the growth of many tumor cells, including small-cell lung	
	ARE BIO	cancer, malignant hemopoietic cells, and breast cancer cells. The IC50 values	
		of Fenretinide were 0.3 and 0.4 μM in 222 and UCI 101 ovarian cancer cell	
		lines. Fenretinide showed antitumor activity in selected T-ALL cell lines.	
		Fenretinide inhibited DES activity in CCRF-CEM leukemia cells in a dose and	
		time dependent manner, leading to a concomitant increase of the endogenous	
		cellular dhCer content. Fenretinide (3 µM) induced dhCer accumulation in both	
		CCRF-CEM and Jurkat cells. Fenretinide (> 1 µM) inhibited OVCAR-5 cell	
		proliferation and viability, with 70-90% growth inhibition at 10 μM. Fenretinide	
		(1 μM) significantly inhibited OVCAR-5 invasion after 3 days preincubation.	
In Vivo	Animal experiment		
	Animal models:	HFD-fed male C57BI/6 mice, NOD/SCID mice	
	Dosage form:	Intraperitoneal injection, 10 mg/kg	
	Applications:	Fenretinide (10 mg/kg, i.p.) selectively inhibited ceramide accumulation	
	OE	HFD-fed male C57BI/6 mice. Fenretinide treatment improved glucose	
	And the state of t	tolerance and insulin sensitivity. Addition of 25 mg/kg ketoconazole to	
		Fenretinide in NOD/SCID mice increased 4-HPR plasma levels.	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
		slightly differ with the theoretical value. This is caused by an experimental	
		system error and it is normal.	

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Apraiz, Aintzane., et al. Dihydroceramide accumulation and reactive oxygen species are distinct and nonessential events in 4-HPR-mediated leukemia cell death. Biochemistry and Cell Biology (2012), 90(2), 209-223.
- [2]. Golubkov V, et al. Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Anticancer Res. 2005 Jan-Feb;25(1A):249-53.
- [3]. Anita L. Sabichi, Denver T. Hendricks, Mary A. Bober, Michael J. Birrer. Retinoic acid receptorβexpression and growthinhibition of gynecologic cancer cells by thesynthetic retinoidn-(4-hydroxyphenyl) retinamide. Journal of the National Cancer Institute. 1998, 90(8): 597-605.
- [4]. Bikman, Benjamin T., et al. Fenretinide Prevents Lipid-induced Insulin Resistance by Blocking Ceramide Biosynthesis. Journal of Biological Chemistry (2012), 287(21), 17426-17437.
- [5]. Cooper JP, et al. Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to

increase systemic exposure. Br J Pharmacol. 2011 Jul;163(6):1263-75.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE BIO





